Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Patients With Moderate or Severe COVID-19
NCT04355676Phase 2Withdrawn
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of selinexor in coronavirus disease 2019 (COVID-19), sponsored by Karyopharm Therapeutics Inc.. Planned start Apr 2020; status: withdrawn.
02
Drugs
selinexor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04355676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355676.